For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporte ...
SGLT2 inhibitors were associated with better cardioprotective effects among older adults than younger adults with type 2 diabetes.
Researchers have found in a new study that SGLT2 inhibitors may have disease-modifying effects in nonsevere aortic stenosis ...
If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
The Brighterside of News on MSN2d
First of its kind drug significantly reduces heart attacks and strokesA recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Medpage Today on MSN2d
SGLT2 Inhibitors May Slow Nonsevere Aortic Stenosis ProgressionFor the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...
China: A recent study published in the Journal of Diabetes and its Complications highlighted dapagliflozin's (DAPA) ...
A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
Investigators compared the outcomes of patients with type 2 diabetes who continued versus stopped metformin after progressing to stage 4 chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback